Caplin Point Stock Surges 25% After FIIs Buy, 10 ANDAs Acquired

• Caplin Point Laboratories Ltd shares surged on January 1, 2026, after a 25% decline over the past year.
• Foreign Institutional Investors (FIIs) significantly increased their stake from 3.7% in Sept 2024 to 6.5% by Sept 2025, buying opportunistically during the stock's fall.
• The company acquired 10 approved ANDAs for injectable and ophthalmic products from a multinational generic pharma company, targeting an addressable market of $473.2 million.
• These ANDAs grant permission to sell drugs in regulated markets like the US, signaling future earnings potential and strengthening the company's US portfolio.
• The acquisition includes oncology injectables, to be commercialized via a new cancer unit, with plans for expansion into Mexico, Canada, Europe, and Brazil.

Why It Matters: FII buying and strategic ANDA acquisitions fueled Caplin Point's stock rally, signaling strong future growth.